tiprankstipranks
Trending News
More News >
NexImmune (NEXI)
OTHER OTC:NEXI
Advertisement

NexImmune (NEXI) AI Stock Analysis

Compare
160 Followers

Top Page

NEXI

NexImmune

(OTC:NEXI)

Select Model
Select Model
Select Model
Underperform 37 (OpenAI - 4o)
Rating:37Underperform
Price Target:
NexImmune's overall score reflects significant financial instability and operational inefficiencies. The lack of revenue and consistent losses are major concerns, overshadowing any technical or valuation aspects. The absence of earnings and a dividend yield further diminish its investment appeal.

NexImmune (NEXI) vs. SPDR S&P 500 ETF (SPY)

NexImmune Business Overview & Revenue Model

Company DescriptionNexImmune (NEXI) is a biotechnology company operating in the healthcare sector, specializing in the development of novel therapies that harness the body's own immune system to combat cancer and other diseases. The company focuses on leveraging its proprietary Artificial Immune Modulation (AIM) technology platform to develop a new class of precision immuno-medicines designed to orchestrate a specific immune response by directing the function of antigen-specific T cells.
How the Company Makes MoneyNexImmune generates revenue primarily through the development and commercialization of its immunotherapy products. The company is engaged in clinical trials and preclinical research to bring its therapies to market. Revenue streams include potential partnerships and collaborations with larger pharmaceutical companies, licensing agreements, and, eventually, product sales if and when its therapies receive regulatory approval. Additionally, NexImmune may receive milestone payments and royalties based on the success and commercialization of its products developed through collaborations.

NexImmune Financial Statement Overview

Summary
NexImmune faces significant financial challenges, with no revenue and consistent losses indicating strategic changes are needed. Despite low leverage, the low equity ratio and negative return on equity are concerns. The cash flow situation highlights the need for better cash management.
Income Statement
30
Negative
NexImmune has recorded no revenue over the past years, highlighting a significant challenge in generating sales. The gross profit margins are negative, reflecting high costs relative to revenue. The net income has shown volatility with a substantial loss in the recent period, indicating profitability issues. The company's EBIT and EBITDA margins are also negative, indicating operational inefficiencies.
Balance Sheet
40
Negative
NexImmune's balance sheet reveals a low debt-to-equity ratio, suggesting a conservative use of debt. However, the negative return on equity indicates that the company is not generating profits from shareholders' investments. The equity ratio is low due to significant liabilities relative to assets, indicating potential financial instability.
Cash Flow
35
Negative
The cash flow statement shows consistent negative free cash flow, reflecting cash outflows exceeding inflows, which could challenge sustainability without external funding. The operating cash flow to net income ratio is negative, indicating poor cash generation from operations. The company needs to improve cash management to ensure liquidity.
BreakdownTTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue2.12M0.000.000.000.000.00
Gross Profit1.44M-1.02M-1.50M-870.28K-618.99K-436.37K
EBITDA-18.05M-28.17M-61.01M-49.13M-27.56M-20.45M
Net Income-20.62M-32.34M514.18M-51.75M-31.64M-20.30M
Balance Sheet
Total Assets5.86M8.59M43.06M91.03M11.30M13.72M
Cash, Cash Equivalents and Short-Term Investments2.42M4.65M34.64M81.82M5.10M10.14M
Total Debt0.0068.81K1.02M0.0019.12M53.63M
Total Liabilities4.94M5.08M10.76M7.27M27.06M3.11M
Stockholders Equity920.54K3.51M32.30M83.76M-15.75M10.61M
Cash Flow
Free Cash Flow-66.28M-31.48M-52.45M-48.14M-27.27M-20.66M
Operating Cash Flow-17.61M-31.43M-51.19M-45.79M-26.40M-19.42M
Investing Cash Flow-43.88M-44.49K50.32M-53.81M221.94K9.42M
Financing Cash Flow3.14M0.005.18M124.89M22.08M18.76M

NexImmune Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.09
Negative
100DMA
0.18
Negative
200DMA
Market Momentum
MACD
-0.03
Positive
RSI
13.97
Positive
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEXI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.09, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 13.97 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEXI.

NexImmune Risk Analysis

NexImmune disclosed 95 risk factors in its most recent earnings report. NexImmune reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

NexImmune Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$137.92B22.1132.08%2.84%3.69%501.26%
50
Neutral
$139.55M-0.83-58.44%-31.23%14.92%
47
Neutral
$814.17M-1.83-55.82%636.99%27.10%
43
Neutral
$32.10M-0.20239.23%-53.61%-93.14%
42
Neutral
$125.54M-0.5546.68%-36.29%36.16%
37
Underperform
$279.00
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NEXI
NexImmune
0.01
-0.20
-95.24%
SLRX
Salarius Pharmaceuticals
4.15
-17.60
-80.92%
SCNI
Scinai Immunotherapeutics
1.36
-2.35
-63.34%
QNRX
Quoin Pharmaceuticals
7.30
-9.76
-57.21%
EVAX
Evaxion Biotech
4.74
-10.56
-69.02%
GRI
GRI Bio
1.97
-4.43
-69.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 15, 2025